Navigation Links
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Date:5/21/2013

roved lung function as measured by Forced Expiratory Volume in one second (FEV1) area under the curve from time zero to 24 hours post dose. Multiple secondary physiological (lung function) and pharmacokinetic endpoints will also be evaluated. Top-line results are expected in early 2014 and will form the basis of the future clinical development of PSX1002. For more information, see clinicaltrials.org.

Notes for Editors

About Prosonix        http://www.prosonix.co.uk

Prosonix is an innovative speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines by design.

Prosonix' ultrasonic particle engineering technology enables it to design and engineer mono and combination drug particles that precisely meet the specific requirements for inhalation, delivering assured formulation performance using simple, cost-effective devices for a range of generic, super-generic and novel products.

Prosonix' pipeline focuses on near- and long-term opportunities, including:

  • PSX1001/PSX1050, a directly substitutable generic version of fluticasone propionate, a potent inhaled corticosteroid (ICS) indicated for asthma and chronic obstructive pulmonary disease (COPD), in a pressurised metered dose inhaler (pMDI)
  • PSX2005, a directly substitutable generic version of a leading ICS/long-acting beta 2 agonist (LABA) combination in development for asthma and COPD in pMDI,
  • PSX1002, a drug-only proprietary formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA) indicated for COPD, in pMDI, and
  • PSX2000 MCP™ Series, novel combination medicines designed specifically for respiratory diseases and based on Multi-component Particles™.

Prosonix has raised more than £22 million from experienced life sciences investors including Ventech, Gi
'/>"/>

SOURCE Prosonix
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Endo International plc (NASDAQ: ... Silva , President and CEO, will present a corporate overview ... York City on Wednesday, May 20, 2015 at ... audio archive for the event will be available on the ... and then the link to the event. Participants should allow ...
(Date:5/6/2015)... 2015  Oxis Biotech, Inc. (OXIS), a wholly owned ... today that Cassian Yee , M.D., Professor, Department ... the University of Texas MD Anderson Cancer Center joined ... Department of Immunology, Division of Cancer Medicine, and Director, ... at the University of Texas MD Anderson Cancer Center.  ...
(Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
(Date:5/5/2015)... 2015  23andMe, Inc., the leading personal genetics company, ... Study in collaboration with Pfizer Inc. The companies ... more commonly known as lupus, into the study to ... is also in collaboration with the Lupus Research Institute, ... Approximately 1.5 million people in the U.S. ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... Raju Kucherlapati , Professor of Genetics at Harvard ... making—will be addressing the Controlled Release Society on the subject of ... , , ... diagnosed with non small cell lung cancer before 2003, there were ...
... JERUSALEM , June 15, ... ), a developer of,alternative drug delivery systems, announced today ... presented by Chief Scientific Officer Dr. Miriam,Kidron , ... American,Diabetes Association, to be held in Orlando, Florida ...
... CARLSBAD, Calif. , June 15 Isis Pharmaceuticals, Inc. (Nasdaq: ... this series of conference calls focused on the drugs in Isis, development pipeline. ... will be held on Thursday, June 17, 2010 at 12:00 ... Isis, Web site. , , , ...
Cached Biology Technology:Personalized Treatments for Cancer Are Revolutionizing Patient Care 2Personalized Treatments for Cancer Are Revolutionizing Patient Care 3Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010 2Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010 3Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 2Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17 3
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... DUBLIN , Mar. 20, 2015 Research ... announced the addition of the "India Sensors ... their offering. The sensor market is ... through 2020 Consumer electronics, automotive, industrial ... for sensors in the country. In addition, adoption ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... shrimp-like creature at the heart of the Antarctic food ... Southern Ocean with iron stimulating the growth of ... capacity for natural storage of carbon dioxide. ... Oceanography , an international team of researchers describe how ...
... viable future biofuel especially if harvested in summer. ... could provide an important alternative to terrestrial grown biofuels; ... a seasonal basis. Harvesting the kelp in July when ... sugar release for biofuel production. , "The storage carbohydrate ...
... by women of advanced maternal age (over 35 years) ... of meiosis a critical process of chromosome duplication ... of oocytes and sperm and leading to abnormalities ... failure, pregnancy loss or, more rarely, the birth of ...
Cached Biology News:Antarctic krill help to fertilize Southern Ocean with iron 2Biofuels from the sea 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 2Could ovarian stimulation cause an increase in oocyte chromosome abnormalities? 3
Request Info...
Imject Freund's Complete Adjuvant (FCA)...
... Degranulation, the secretion of cytoplasmic ... the inflammatory response of leukocytes (e.g. ... In addition to histamine, these secretory ... heparin, cytokines, chemokines, and many proteases ...
... Safe DNA gel stain was developed specifically for ... bromide for staining DNA in agarose or acrylamide ... mutagenic than ethidium bromide but SYBR Safe stain's ... bromide. SYBR Safe stain comes as a premixed ...
Biology Products: